Patients Sue Novo Nordisk, Eli Lilly Over Rare Vision Loss Linked to GLP-1 Drugs

Dozens of lawsuits allege that Ozempic, Wegovy, and Zepbound caused non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of vision loss. The claims are emerging litigation against major pharma firms; causation is not yet established in court. This could affect drug liability and regulatory scrutiny, but market impact is uncertain.